Literature DB >> 1713213

Recombinant human pim-1 protein exhibits serine/threonine kinase activity.

D Hoover1, M Friedmann, R Reeves, N S Magnuson.   

Abstract

The protein predicted by the sequence of the human pim-1 proto-oncogene shares extensive homology with known serine/threonine protein kinases, and yet the human Pim-1 enzyme has previously been reported to exhibit protein tyrosine kinase activity both in vitro and in vivo. Recently a new class of protein kinases has been identified which exhibits both protein-serine/threonine and protein-tyrosine kinase activities. We therefore investigated the possibility that the human Pim-1 kinase likewise possesses such bifunctional enzymatic phosphorylating activities. A full-length human pim-1 cDNA was subcloned into the bacterial vector pGEX-2T and the Pim-1 protein expressed as a fusion product with bacterial glutathione S-transferase (GST). The hybrid GST-Pim-1 fusion protein was affinity purified on a glutathione-Sepharose column prior to treatment with thrombin for cleavage of the Pim-1 protein from the transferase. Pim-1 was purified and the identity of recombinant protein confirmed by amino-terminal sequence analysis. Pim-1 was tested for kinase activity with a variety of proteins and peptides known to be substrates for either mammalian protein-serine/threonine or protein-tyrosine kinases and was found to phosphorylate serine/threonine residues exclusively in vitro. Both the Pim-1-GST fusion protein and the isolated Pim-1 protein exhibited only serine/threonine phosphorylating activity under all in vitro conditions tested. Pim-1 phosphorylated purified mammalian histone H1 with a Km of approximately 51 microM. Additionally, Pim-1 exhibited low levels of serine/threonine autophosphorylating activity. These observations place the human Pim-1 in a small select group of cytoplasmic transforming oncogenic kinases, including the protein kinase C, the Raf/Mil, and the Mos subfamilies, exhibiting serine/threonine phosphorylating activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713213

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.

Authors:  Nithya Krishnan; Huiqi Pan; Donna J Buckley; Arthur Buckley
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

Review 2.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

3.  Characterization of the testes-specific pim-1 transcript in rat.

Authors:  D Wingett; R Reeves; N S Magnuson
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

Review 4.  Nuclear and mitochondrial signalling Akts in cardiomyocytes.

Authors:  Shigeki Miyamoto; Marta Rubio; Mark A Sussman
Journal:  Cardiovasc Res       Date:  2009-03-11       Impact factor: 10.787

Review 5.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

6.  PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311.

Authors:  J Yang; K Liu; J Yang; B Jin; H Chen; X Zhan; Z Li; L Wang; X Shen; M Li; W Yu; Z Mao
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

7.  Searching for depolarization-induced genes that modulate synaptic plasticity and neurotrophin-induced genes that mediate neuronal differentiation.

Authors:  H R Herschman; G D Ferguson; J D Feldman; R Farias-Eisner; L Vician
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

Review 8.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

9.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

10.  In vivo analysis of Pim-1 deficiency.

Authors:  P W Laird; N M van der Lugt; A Clarke; J Domen; K Linders; J McWhir; A Berns; M Hooper
Journal:  Nucleic Acids Res       Date:  1993-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.